MedWatch

Novo Seeds: better than anything we could have imagined

Novo Seeds, a major shareholder in Galecto Biotech, is thrilled with the recently published data on the biotech company’s lead candidate, which it struck a lucrative deal with Bristol-Myers Squibb for a few years back.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

2017 var et rekordår for kapitalrejsninger i Skandinavien

Skandinaviske life science-selskaber rejste ligeså mange penge i 2017 som i de tre foregående år tilsammen, viser en ny rapport fra svenske Industrifonden. Sverige førte ikke overraskende an, men der var også fremgang at spore i Danmark og Norge.

Related articles